Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer

Trastuzumab improves outcomes among patients with HER2-positive breast cancer but is associated with a risk of treatment-induced cardiotoxicity (TIC). It is unclear how frequently TIC leads to trastuzumab interruption outside of prospective trials, and how TIC is managed in clinical practice. Patien...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Breast Cancer Res Treat
Asıl Yazarlar: Yu, Anthony F., Yadav, Nandini U., Lung, Betty Y., Eaton, Anne A., Thaler, Howard T., Hudis, Clifford A., Dang, Chau T., Steingart, Richard M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4970316/
https://ncbi.nlm.nih.gov/pubmed/25552363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3253-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller